Cargando…

Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer

BACKGROUND: Although the androgen receptor (AR) is frequently expressed in breast cancer, its relevance in the disease is not fully understood. In addition, the relevance of AR in determining tamoxifen treatment efficiency requires evaluation. PURPOSE: To investigate the tamoxifen predictive relevan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hilborn, Erik, Gacic, Jelena, Fornander, Tommy, Nordenskjöld, Bo, Stål, Olle, Jansson, Agneta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742586/ https://www.ncbi.nlm.nih.gov/pubmed/26742006 http://dx.doi.org/10.1038/bjc.2015.464

Ejemplares similares

C–X–C ligand 10 and C–X–C receptor 3 status can predict tamoxifen treatment response in breast cancer patients
por: Hilborn, Erik, et al.
Publicado: (2014)

17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer
por: Sivik, Tove, et al.
Publicado: (2012)

Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer
por: Jerevall, Piiha-Lotta, et al.
Publicado: (2010)

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer
por: Fohlin, Helena, et al.
Publicado: (2020)

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer
por: Weiner, M., et al.
Publicado: (2013)

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer
por: Nordenskjöld, Anna, et al.
Publicado: (2016)

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
por: Bostner, Josefine, et al.
Publicado: (2017)

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
por: Bostner, Josefine, et al.
Publicado: (2012)

Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer
por: Hilborn, Erik, et al.
Publicado: (2017)

RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer
por: Fohlin, Helena, et al.
Publicado: (2020)

Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial
por: Dar, Huma, et al.
Publicado: (2021)

The regulation of hydroxysteroid 17β-dehydrogenase type 1 and 2 gene expression in breast cancer cell lines by estradiol, dihydrotestosterone, microRNAs, and genes related to breast cancer
por: Hilborn, Erik, et al.
Publicado: (2017)

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk
por: van ‘t Veer, Laura J., et al.
Publicado: (2017)

BASP1 interacts with oestrogen receptor α and modifies the tamoxifen response
por: Marsh, Lindsey A, et al.
Publicado: (2017)

Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
por: Nordenskjöld, Anna, et al.
Publicado: (2023)

Oestrogen and androgen receptors in melanoma.
por: Rümke, P., et al.
Publicado: (1980)

Expression of oestrogen receptor-β in oestrogen receptor-α negative human breast tumours
por: Skliris, G P, et al.
Publicado: (2006)

PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer
por: Karlsson, Elin, et al.
Publicado: (2018)

The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials
por: Karlsson, Elin, et al.
Publicado: (2013)

Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines.
por: Langdon, S. P., et al.
Publicado: (1990)

Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines
por: Ferlini, C, et al.
Publicado: (1999)

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
por: Wegman, Pia, et al.
Publicado: (2005)

High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer
por: Paulsson, Janna, et al.
Publicado: (2016)

The CAG repeat polymorphism in the Androgen receptor gene modifies the risk for hypospadias in Caucasians
por: Adamovic, Tatjana, et al.
Publicado: (2012)

The influence of tamoxifen treatment on the oestrogen receptor in metachronous contralateral breast cancer
por: Kaas, R, et al.
Publicado: (2003)

A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate
por: Scandlyn, M J, et al.
Publicado: (2008)

Proceedings: Oestrogen and androgen receptors in human breast cancer.
por: Engelsman, E., et al.
Publicado: (1974)

The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype
por: Veenstra, Cynthia, et al.
Publicado: (2019)

IP6K2 predicts favorable clinical outcome of primary breast cancer
por: Sandström, Josefine, et al.
Publicado: (2021)

Oestrogen receptor β and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment
por: Miller, W R, et al.
Publicado: (2006)

Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial
por: Rosell, J, et al.
Publicado: (2011)

Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis.
por: Ferlini, C., et al.
Publicado: (1997)

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
por: Schroeder, Brock, et al.
Publicado: (2017)

Characterization of Aromatase Expression in the Adult Male and Female Mouse Brain. I. Coexistence with Oestrogen Receptors α and β, and Androgen Receptors
por: Stanić, Davor, et al.
Publicado: (2014)

Studies of a co-chaperone of the androgen receptor, FKBP52, as candidate for hypospadias
por: Beleza-Meireles, Ana, et al.
Publicado: (2007)

The origins of oestrogen receptor negative breast cancer
por: Allred, D Craig
Publicado: (2007)

Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy
por: Henry, N L, et al.
Publicado: (2010)

Oestrogens and oestrogen receptors in prostate cancer
por: Kowalska, Karolina, et al.
Publicado: (2016)

Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature
por: Johansson, Annelie, et al.
Publicado: (2022)

Complementary yet distinct roles for oestrogen receptor-α and oestrogen receptor-β in mouse mammary epithelial proliferation
por: Clarke, Robert B
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_4pn67oo9k8lsnuk2qahcalqot4